Infection Viral
45
4
4
28
Key Insights
Highlights
Success Rate
93% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
4.4%
2 terminated out of 45 trials
93.3%
+6.8% vs benchmark
7%
3 trials in Phase 3/4
14%
4 of 28 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 28 completed trials
Clinical Trials (45)
Microbial Cell-free Metagenomic Sequencing for Suspected Infections in Adult Immunocompromised Outpatients
Predictive Biomarkers of Secondary Aggravation in Covid-19 Suspect Patient
biomArkers to differeNtiate bacTerial From vIral iNfEctions
Development and Validation of (Bio)Sensors for the Identification of Pathogens
Towards Novel BIOmarkers to Diagnose SEPsis on the Emergency Room
RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection
COVID-19 - Multicentre Study on Nosocomial Transmission of SARS-CoV-2 Virus: an Ancillary Study (NOSO-COR IMMUNO)
COVID-19 - Multicenter Study on Nosocomial Transmission of SARS-CoV-2 Virus
Xofluza-Wearables Feasibility-Study
Access MeMed BV Assay Clinical Study Collection Protocol - Infectious Adult and Pediatric Cohorts
Xanthohumol and Viral Infections (XL)
Nosocomial Influenza Surveillance of 2022 - 2027 Seasonal Period
Covid-19 and Prevention of Malnutrition After Confinement by Dentists
Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults
TARGet Kids! COVID-19 Study of Children and Families
Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults
A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults
Predicting Severity and Disease Progression in Influenza-like Illness (Including COVID-19)
A Phase 1/2 Study to Determine Safety and Immunogenicity of Two COVID 19 Vaccines VB10.2129 (RBD Candidate) and VB10.2210 (T Cell Candidate) Previously Vaccinated in Healthy Adult Volunteers
PREdiction of DIagnosed Covid-19 infecTion in IUC Patients